pioglitazone has been researched along with Dyslipidemia in 43 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| " After 12 weeks' treatment, the pioglitazone group showed a highly significant reduction in body weight (83±10." | 9.24 | Pioglitazone attenuates cardiometabolic risk factors in non-diabetic patients with dyslipidemia. ( Akhtar, L; Hussain, M; Shad, MN, 2017) |
| " A total of 522 patients with hypertension and/or dyslipidemia who had one or more silent cerebral infarcts, advanced carotid atherosclerosis or microalbuminuria at baseline were randomly treated with (n=254) or without pioglitazone (n=268) and observed for a medium of 672 days." | 9.19 | Effects of pioglitazone on macrovascular events in patients with type 2 diabetes mellitus at high risk of stroke: the PROFIT-J study. ( Kawamori, R; Kitagawa, K; Kitakaze, M; Matsuhisa, M; Matsumoto, M; Onuma, T; Watada, H; Yamasaki, Y; Yamazaki, T; Yoshii, H, 2014) |
| " We studied the effects of pioglitazone (PIO) and rosiglitazone (ROSI) treatments on serum lipoprotein particle concentrations and sizes in type 2 diabetic patients with dyslipidemia." | 9.12 | Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. ( Buse, JB; Deeg, MA; Goldberg, RB; Jacober, SJ; Kendall, DM; Khan, MA; Perez, AT; Tan, MH; Zagar, AJ, 2007) |
| "The purpose of this work was to compare the influences of sulforaphane (SFN) to those of the standard insulin sensitizer pioglitazone (PIO) on high fructose diet (HFrD)-induced insulin resistance, dyslipidemia, hepatosteatosis, and vascular dysfunction in rats." | 7.91 | Comparison of the effects of sulforaphane and pioglitazone on insulin resistance and associated dyslipidemia, hepatosteatosis, and endothelial dysfunction in fructose-fed rats. ( Gameil, NM; Shawky, NM; Shehatou, GSG; Suddek, GM, 2019) |
| " Pioglitazone treatment (3 mg/kg body weight/d for 6 weeks), a peroxisome proliferator-activated receptor γ agonist, reversibly improved atherogenic dyslipidemia and insulin resistance and fully restored flow-mediated dilation with persistent benefits." | 7.77 | Rhesus macaques develop metabolic syndrome with reversible vascular dysfunction responsive to pioglitazone. ( Cheng, H; Ding, Y; Han, C; Hou, N; Huang, PL; Li, C; Li, K; Liu, N; Liu, Y; Mao, J; Raab, S; Sebokova, E; Shang, S; Song, Z; Wang, H; Wang, J; Xue, L; Zhang, H; Zhang, R; Zhang, X; Zhang, Y; Zheng, W; Zhu, T, 2011) |
| " Baseline parameters came from a multi-center, double-blind trial comparing lipid and glycemic effects of pioglitazone (n = 400) and rosiglitazone (n = 402) among individuals with T2DM and untreated dyslipidemia." | 7.74 | Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US. ( Baran, RW; Minshall, ME; Pandya, BJ; St Charles, M; Tunis, SL, 2008) |
| " The aim of this study was to investigate the capacity of chiglitazar to improve insulin resistance and dyslipidemia in monosodium L-glutamate (MSG) obese rats and to determine whether its lipid-lowering effect is mediated through its activation of PPARalpha." | 7.73 | The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats. ( Chen, YT; Li, PP; Liu, Q; Lu, XP; Ning, ZQ; Shan, S; Shen, ZF; Sun, SJ; Xie, MZ, 2006) |
| "Dyslipidemia in patients with type 2 diabetes is characterized by elevated triglyceride levels, decreased high-density lipoprotein (HDL) cholesterol, and a predominance of small dense low-density lipoprotein (LDL) particles." | 6.76 | PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia. ( Forst, T; Fuchs, W; Lehmann, U; Lobmann, R; Merke, J; Müller, J; Pfützner, A; Schöndorf, T; Tschöpe, D, 2011) |
| "Treatment with pioglitazone, BCP, BCP + CB2R antagonist, AM630, or BCP + PPAR-γ antagonist, BADGE was started from the 9th week and continued till the 12th week." | 5.51 | Beta-caryophyllene protects against diet-induced dyslipidemia and vascular inflammation in rats: Involvement of CB2 and PPAR-γ receptors. ( El-Fayoumi, HM; Mahmoud, MF; Youssef, DA, 2019) |
| "Biochemical markers of NAFLD worsened over time." | 5.40 | Resistant nonalcoholic fatty liver disease amelioration with rosuvastatin and pioglitazone combination therapy in a patient with metabolic syndrome. ( Black, CA; Fleming, JW; Malinowski, SS; Miller, KH; Riche, DM; Wofford, MR, 2014) |
| " After 12 weeks' treatment, the pioglitazone group showed a highly significant reduction in body weight (83±10." | 5.24 | Pioglitazone attenuates cardiometabolic risk factors in non-diabetic patients with dyslipidemia. ( Akhtar, L; Hussain, M; Shad, MN, 2017) |
| "Fenofibrate is a peroxisome proliferator-activated receptor-α that has been clinically used to treat dyslipidemia and insulin resistance." | 5.19 | Fenofibrate increases serum vaspin by upregulating its expression in adipose tissue. ( Chen, M; Deng, D; Fang, Z; Hu, H; Luo, L; Wang, Y; Xu, M, 2014) |
| " A total of 522 patients with hypertension and/or dyslipidemia who had one or more silent cerebral infarcts, advanced carotid atherosclerosis or microalbuminuria at baseline were randomly treated with (n=254) or without pioglitazone (n=268) and observed for a medium of 672 days." | 5.19 | Effects of pioglitazone on macrovascular events in patients with type 2 diabetes mellitus at high risk of stroke: the PROFIT-J study. ( Kawamori, R; Kitagawa, K; Kitakaze, M; Matsuhisa, M; Matsumoto, M; Onuma, T; Watada, H; Yamasaki, Y; Yamazaki, T; Yoshii, H, 2014) |
| " In this study, we administered pioglitazone and pitavastatin for 16 weeks to 18 patients who had type 2 diabetes complicated by dyslipidemia and then investigated the influence of these 2 drugs on MDA-LDL(i." | 5.15 | [Study of MDA-LDL by pioglitazone and pitavastatin in patients with type 2 diabetes]. ( Hayashi, S; Taguchi, A, 2011) |
| "Three-month treatment with pioglitazone improved glycaemic control, homeostasis model assessment for insulin resistance (HOMA), dyslipidaemia and liver function tests in association with a marked increase in serum HMW adiponectin level." | 5.14 | Withdrawal of pioglitazone in patients with type 2 diabetes mellitus. ( Asano, T; Hiramatsu, S; Iida, M; Iwase, M; Ogo, A; Sakai, Y; Sasaki, N; Yoshizumi, H, 2010) |
| " We studied the effects of pioglitazone (PIO) and rosiglitazone (ROSI) treatments on serum lipoprotein particle concentrations and sizes in type 2 diabetic patients with dyslipidemia." | 5.12 | Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. ( Buse, JB; Deeg, MA; Goldberg, RB; Jacober, SJ; Kendall, DM; Khan, MA; Perez, AT; Tan, MH; Zagar, AJ, 2007) |
| " This study compared the efficacy of tesaglitazar with that of pioglitazone as adjunctive therapy to atorvastatin in subjects with abdominal obesity and dyslipidemia." | 5.12 | The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin. ( Lindberg, MB; Ohman, KP; Ose, L; Retterstøl, K; Svensson, M; Tonstad, S, 2007) |
| "This paper reviewed the effects of pioglitazone and rosiglitazone on atherogenic diabetic dyslipidemia, in particular on small dense low-density lipoprotein particles." | 4.84 | The differential effects of thiazolidindiones on atherogenic dyslipidemia in type 2 diabetes: what is the clinical significance? ( Berneis, K; Christ, ER; Rini, GB; Rizzo, M; Spinas, GA, 2008) |
| "Pioglitazone is an antihyperglycaemic agent that, in the presence of insulin resistance, increases hepatic and peripheral insulin sensitivity, thereby inhibiting hepatic gluconeogenesis and increasing peripheral and splanchnic glucose uptake." | 4.83 | Pioglitazone: a review of its use in type 2 diabetes mellitus. ( Easthope, S; Keating, GM; Plosker, GL; Robinson, DM; Waugh, J, 2006) |
| " Pioglitazone, an antidiabetic agent that acts primarily by decreasing insulin resistance, improves sensitivity to insulin in muscle and adipose tissue and inhibits hepatic gluconeogenesis." | 4.82 | The metabolic basis of atherogenic dyslipidemia. ( Vinik, AI, 2005) |
| "The purpose of this work was to compare the influences of sulforaphane (SFN) to those of the standard insulin sensitizer pioglitazone (PIO) on high fructose diet (HFrD)-induced insulin resistance, dyslipidemia, hepatosteatosis, and vascular dysfunction in rats." | 3.91 | Comparison of the effects of sulforaphane and pioglitazone on insulin resistance and associated dyslipidemia, hepatosteatosis, and endothelial dysfunction in fructose-fed rats. ( Gameil, NM; Shawky, NM; Shehatou, GSG; Suddek, GM, 2019) |
| " Pioglitazone treatment (3 mg/kg body weight/d for 6 weeks), a peroxisome proliferator-activated receptor γ agonist, reversibly improved atherogenic dyslipidemia and insulin resistance and fully restored flow-mediated dilation with persistent benefits." | 3.77 | Rhesus macaques develop metabolic syndrome with reversible vascular dysfunction responsive to pioglitazone. ( Cheng, H; Ding, Y; Han, C; Hou, N; Huang, PL; Li, C; Li, K; Liu, N; Liu, Y; Mao, J; Raab, S; Sebokova, E; Shang, S; Song, Z; Wang, H; Wang, J; Xue, L; Zhang, H; Zhang, R; Zhang, X; Zhang, Y; Zheng, W; Zhu, T, 2011) |
| " Baseline parameters came from a multi-center, double-blind trial comparing lipid and glycemic effects of pioglitazone (n = 400) and rosiglitazone (n = 402) among individuals with T2DM and untreated dyslipidemia." | 3.74 | Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US. ( Baran, RW; Minshall, ME; Pandya, BJ; St Charles, M; Tunis, SL, 2008) |
| " The aim of this study was to investigate the capacity of chiglitazar to improve insulin resistance and dyslipidemia in monosodium L-glutamate (MSG) obese rats and to determine whether its lipid-lowering effect is mediated through its activation of PPARalpha." | 3.73 | The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats. ( Chen, YT; Li, PP; Liu, Q; Lu, XP; Ning, ZQ; Shan, S; Shen, ZF; Sun, SJ; Xie, MZ, 2006) |
| "Statin therapy is safe in patients with prediabetes/T2DM and NASH." | 2.84 | Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial. ( Bril, F; Cusi, K; Hecht, J; Lomonaco, R; Orsak, B; Portillo Sanchez, P; Tio, F, 2017) |
| "Type 2 diabetes is a major risk factor for chronic kidney disease, which substantially increases the risk of cardiovascular disease mortality." | 2.79 | Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study. ( Hanefeld, M; Herz, M; Lincoff, AM; Malmberg, K; Meyer-Reigner, S; Mudie, N; Ruilope, L; Viberti, G; Wieczorek Kirk, D, 2014) |
| "Dyslipidemia in patients with type 2 diabetes is characterized by elevated triglyceride levels, decreased high-density lipoprotein (HDL) cholesterol, and a predominance of small dense low-density lipoprotein (LDL) particles." | 2.76 | PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia. ( Forst, T; Fuchs, W; Lehmann, U; Lobmann, R; Merke, J; Müller, J; Pfützner, A; Schöndorf, T; Tschöpe, D, 2011) |
| "Though gout is more prevalent in men than women, it remains unclear whether gender influences risk factors for incident gout." | 2.61 | Gender-specific risk factors for gout: a systematic review of cohort studies. ( Belcher, J; Evans, PL; Hay, CA; Mallen, CD; Prior, JA; Roddy, E, 2019) |
| "Statins have a primary role in the treatment of dyslipidemia in people with type 2 diabetes, defined as triglyceride levels >200 mg/dl and HDL cholesterol levels <40 mg/dL." | 2.55 | Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins. ( Anabtawi, A; Miles, JM; Moriarty, PM, 2017) |
| "Nonalcoholic fatty liver disease is the most common cause of liver dysfunction in the western world because of its close association with obesity, insulin resistance and dyslipidaemia." | 2.52 | Nonalcoholic fatty liver disease: new treatments. ( Anstee, QM; Day, CP; Hardy, T, 2015) |
| "Treatment with Rosiglitazone should be reconsidered because of a potential cardiovascular risk." | 2.44 | [Therapy with glitazones--a risk for cardiovascular disease?]. ( Erdmann, E; Hoppe, UC; Michels, G; Rottlaender, D, 2007) |
| "Treatment with pioglitazone, BCP, BCP + CB2R antagonist, AM630, or BCP + PPAR-γ antagonist, BADGE was started from the 9th week and continued till the 12th week." | 1.51 | Beta-caryophyllene protects against diet-induced dyslipidemia and vascular inflammation in rats: Involvement of CB2 and PPAR-γ receptors. ( El-Fayoumi, HM; Mahmoud, MF; Youssef, DA, 2019) |
| "Biochemical markers of NAFLD worsened over time." | 1.40 | Resistant nonalcoholic fatty liver disease amelioration with rosuvastatin and pioglitazone combination therapy in a patient with metabolic syndrome. ( Black, CA; Fleming, JW; Malinowski, SS; Miller, KH; Riche, DM; Wofford, MR, 2014) |
| "Pioglitazone has been shown to significantly reduce cardiovascular adverse outcomes, while preliminary data on IBTs are very encouraging as well." | 1.39 | Non-glycemic effects of pioglitazone and incretin-based therapies. ( Avogaro, A; Montalto, G; Rizvi, AA; Rizzo, M, 2013) |
| "Fenofibrate treatment significantly improved lipoprotein metabolism toward a less atherogenic phenotype but did not affect insulin sensitivity." | 1.33 | PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia. ( Fiévet, C; Fruchart, JC; Hennuyer, N; Mezdour, H; Staels, B; Tailleux, A; Torpier, G, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 18 (41.86) | 29.6817 |
| 2010's | 23 (53.49) | 24.3611 |
| 2020's | 2 (4.65) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, W | 1 |
| Liu, K | 1 |
| Wood, HB | 1 |
| McCann, ME | 1 |
| Doebber, TW | 1 |
| Chang, CH | 1 |
| Akiyama, TE | 1 |
| Einstein, M | 1 |
| Berger, JP | 1 |
| Meinke, PT | 1 |
| Aggarwal, H | 1 |
| Pathak, P | 1 |
| Kumar, Y | 1 |
| Jagavelu, K | 1 |
| Dikshit, M | 1 |
| Krishnappa, M | 1 |
| Patil, K | 1 |
| Parmar, K | 1 |
| Trivedi, P | 1 |
| Mody, N | 1 |
| Shah, C | 1 |
| Faldu, K | 1 |
| Maroo, S | 1 |
| Parmar, D | 1 |
| Yamada, T | 1 |
| Hiraoka, E | 1 |
| Miyazaki, T | 1 |
| Sato, J | 1 |
| Ban, N | 1 |
| Anabtawi, A | 1 |
| Moriarty, PM | 1 |
| Miles, JM | 1 |
| Bril, F | 1 |
| Portillo Sanchez, P | 1 |
| Lomonaco, R | 1 |
| Orsak, B | 1 |
| Hecht, J | 1 |
| Tio, F | 1 |
| Cusi, K | 1 |
| Hussain, M | 1 |
| Shad, MN | 1 |
| Akhtar, L | 1 |
| Hirano, T | 1 |
| Youssef, DA | 1 |
| El-Fayoumi, HM | 1 |
| Mahmoud, MF | 1 |
| Shawky, NM | 1 |
| Shehatou, GSG | 1 |
| Suddek, GM | 1 |
| Gameil, NM | 1 |
| Corey, KE | 1 |
| Wilson, LA | 1 |
| Altinbas, A | 1 |
| Yates, KP | 1 |
| Kleiner, DE | 1 |
| Chung, RT | 1 |
| Krauss, RM | 1 |
| Chalasani, N | 2 |
| Evans, PL | 1 |
| Prior, JA | 1 |
| Belcher, J | 1 |
| Hay, CA | 1 |
| Mallen, CD | 1 |
| Roddy, E | 1 |
| Rizzo, M | 2 |
| Avogaro, A | 1 |
| Montalto, G | 1 |
| Rizvi, AA | 1 |
| Chen, M | 1 |
| Deng, D | 1 |
| Fang, Z | 1 |
| Xu, M | 1 |
| Hu, H | 1 |
| Luo, L | 1 |
| Wang, Y | 1 |
| Riche, DM | 1 |
| Fleming, JW | 1 |
| Malinowski, SS | 1 |
| Black, CA | 1 |
| Miller, KH | 1 |
| Wofford, MR | 1 |
| Yoshii, H | 1 |
| Onuma, T | 1 |
| Yamazaki, T | 1 |
| Watada, H | 1 |
| Matsuhisa, M | 1 |
| Matsumoto, M | 1 |
| Kitagawa, K | 1 |
| Kitakaze, M | 1 |
| Yamasaki, Y | 1 |
| Kawamori, R | 1 |
| Ibáñez, L | 1 |
| Ong, KK | 1 |
| López-Bermejo, A | 1 |
| Dunger, DB | 1 |
| de Zegher, F | 1 |
| Perségol, L | 1 |
| Duvillard, L | 1 |
| Monier, S | 1 |
| Brindisi, MC | 1 |
| Bouillet, B | 1 |
| Petit, JM | 1 |
| Vergès, B | 2 |
| Ruilope, L | 1 |
| Hanefeld, M | 1 |
| Lincoff, AM | 1 |
| Viberti, G | 1 |
| Meyer-Reigner, S | 1 |
| Mudie, N | 1 |
| Wieczorek Kirk, D | 1 |
| Malmberg, K | 1 |
| Herz, M | 1 |
| Hardy, T | 1 |
| Anstee, QM | 1 |
| Day, CP | 1 |
| Liu, HJ | 1 |
| Zhang, CY | 1 |
| Song, F | 1 |
| Xiao, T | 1 |
| Meng, J | 1 |
| Zhang, Q | 1 |
| Liang, CL | 1 |
| Li, S | 1 |
| Wang, J | 2 |
| Zhang, B | 1 |
| Liu, YR | 1 |
| Sun, T | 1 |
| Zhou, HG | 1 |
| Derosa, G | 1 |
| Salvadeo, SA | 1 |
| Christ, ER | 1 |
| Rini, GB | 1 |
| Spinas, GA | 1 |
| Berneis, K | 1 |
| Tunis, SL | 1 |
| Minshall, ME | 1 |
| St Charles, M | 1 |
| Pandya, BJ | 1 |
| Baran, RW | 1 |
| Vuppalanchi, R | 1 |
| Iwase, M | 1 |
| Asano, T | 1 |
| Sasaki, N | 1 |
| Yoshizumi, H | 1 |
| Hiramatsu, S | 1 |
| Sakai, Y | 1 |
| Ogo, A | 1 |
| Iida, M | 1 |
| Taguchi, A | 1 |
| Hayashi, S | 1 |
| Pfützner, A | 1 |
| Schöndorf, T | 1 |
| Tschöpe, D | 2 |
| Lobmann, R | 1 |
| Merke, J | 1 |
| Müller, J | 1 |
| Lehmann, U | 1 |
| Fuchs, W | 1 |
| Forst, T | 2 |
| Zhang, X | 1 |
| Zhang, R | 1 |
| Raab, S | 1 |
| Zheng, W | 1 |
| Liu, N | 1 |
| Zhu, T | 1 |
| Xue, L | 1 |
| Song, Z | 1 |
| Mao, J | 1 |
| Li, K | 1 |
| Zhang, H | 1 |
| Zhang, Y | 1 |
| Han, C | 1 |
| Ding, Y | 1 |
| Wang, H | 1 |
| Hou, N | 1 |
| Liu, Y | 1 |
| Shang, S | 1 |
| Li, C | 1 |
| Sebokova, E | 1 |
| Cheng, H | 1 |
| Huang, PL | 1 |
| Shinohara, Y | 1 |
| Hennuyer, N | 1 |
| Tailleux, A | 1 |
| Torpier, G | 1 |
| Mezdour, H | 1 |
| Fruchart, JC | 1 |
| Staels, B | 1 |
| Fiévet, C | 1 |
| Betteridge, DJ | 1 |
| Waugh, J | 1 |
| Keating, GM | 1 |
| Plosker, GL | 1 |
| Easthope, S | 1 |
| Robinson, DM | 1 |
| Vinik, AI | 1 |
| Trogan, E | 1 |
| Feig, JE | 1 |
| Dogan, S | 1 |
| Rothblat, GH | 1 |
| Angeli, V | 1 |
| Tacke, F | 1 |
| Randolph, GJ | 1 |
| Fisher, EA | 1 |
| Li, PP | 1 |
| Shan, S | 1 |
| Chen, YT | 1 |
| Ning, ZQ | 1 |
| Sun, SJ | 1 |
| Liu, Q | 1 |
| Lu, XP | 1 |
| Xie, MZ | 1 |
| Shen, ZF | 1 |
| Berhanu, P | 1 |
| Kipnes, MS | 1 |
| Khan, MA | 2 |
| Perez, AT | 2 |
| Kupfer, SF | 1 |
| Spanheimer, RC | 1 |
| Demissie, S | 1 |
| Fleck, PR | 1 |
| Yoshiuchi, I | 1 |
| Itoh, N | 1 |
| Nakano, M | 1 |
| Tatsumi, C | 1 |
| Yokoyama, K | 1 |
| Matsuyama, T | 1 |
| Deeg, MA | 1 |
| Buse, JB | 1 |
| Goldberg, RB | 1 |
| Kendall, DM | 1 |
| Zagar, AJ | 1 |
| Jacober, SJ | 1 |
| Tan, MH | 1 |
| Tonstad, S | 1 |
| Retterstøl, K | 1 |
| Ose, L | 1 |
| Ohman, KP | 1 |
| Lindberg, MB | 1 |
| Svensson, M | 1 |
| Comaschi, M | 1 |
| Corsi, A | 1 |
| Di Pietro, C | 1 |
| Bellatreccia, A | 1 |
| Mariz, S | 1 |
| Rottlaender, D | 1 |
| Michels, G | 1 |
| Erdmann, E | 2 |
| Hoppe, UC | 1 |
| Eckert, S | 1 |
| Lundershausen, R | 1 |
| Scherbaum, WA | 1 |
| Schnell, O | 1 |
| Standl, E | 1 |
| Schumm-Draeger, PM | 1 |
| Walter, H | 1 |
| Weber, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of 150 mcg Aleglitazar on Renal Function in Patients With Type 2 Diabetes and Moderate Renal Impairment, as Compared to Actos®[NCT01043029] | Phase 2 | 302 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
| Prevalence of NAFLD and Correlation With Its Main Risk Factors Among Egyptian Multicenter National Study[NCT04081571] | 1,080 participants (Anticipated) | Observational | 2019-04-01 | Recruiting | |||
| Effects of a Pioglitazone/Metformin Fixed Combination in Comparison to Metformin in Combination With Glimepiride on Diabetic Dyslipidemia[NCT00770653] | Phase 3 | 305 participants (Actual) | Interventional | 2007-04-30 | Completed | ||
| A Single-Arm, Open-Label, Multicenter Study Evaluating the Triglyceride Changes in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia Following Treatment Conversion From Rosiglitazone to Pioglitazone HCl in Combination With Stable Statin Therapy[NCT00672919] | Phase 4 | 305 participants (Actual) | Interventional | 2003-11-30 | Completed | ||
| Pioglitazone Versus Rosiglitazone in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia[NCT00331487] | Phase 3 | 719 participants (Actual) | Interventional | 2000-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The change between Adiponectin collected at week 24 or final visit and Adiponectin collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | μg/mL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 6.79 |
| Glimepiride 2 mg and Metformin 850 mg BID | 0.72 |
The change between Diastolic Blood Pressure measured at week 24 or final visit and Diastolic Blood Pressure measured at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -1.3 |
| Glimepiride 2 mg and Metformin 850 mg BID | -0.1 |
The change between the value of E-Selectin collected at week 24 or final visit and E-Selectin collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | ng/mL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -3.7 |
| Glimepiride 2 mg and Metformin 850 mg BID | -0.5 |
The change between the 0.30 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | percent (Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 1.3 |
| Glimepiride 2 mg and Metformin 850 mg BID | -0.4 |
The change between the 0.60 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | percent (Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 2.4 |
| Glimepiride 2 mg and Metformin 850 mg BID | -0.5 |
The change between the 1.20 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | percent (Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 3.2 |
| Glimepiride 2 mg and Metformin 850 mg BID | -1.1 |
The change between the 12.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | percent (Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 2.7 |
| Glimepiride 2 mg and Metformin 850 mg BID | -1.3 |
The change between the 3.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | percent (Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 3.3 |
| Glimepiride 2 mg and Metformin 850 mg BID | -.15 |
The change between the 30.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | percent (Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 2.5 |
| Glimepiride 2 mg and Metformin 850 mg BID | -1.3 |
The change between the 6.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | percent (Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 3.1 |
| Glimepiride 2 mg and Metformin 850 mg BID | -1.4 |
The change between the 60.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | percent (Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 2.7 |
| Glimepiride 2 mg and Metformin 850 mg BID | -1.3 |
The change between Fasting Glucose collected at week 24 or final visit and Fasting Glucose collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -21.6 |
| Glimepiride 2 mg and Metformin 850 mg BID | -21.1 |
The change between Fasting Intact Proinsulin collected at week 24 or final visit and Fasting Intact Proinsulin collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | pmol/L (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -5.18 |
| Glimepiride 2 mg and Metformin 850 mg BID | -0.11 |
The change between the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 24 or final visit and Glycosylated Hemoglobin collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -0.83 |
| Glimepiride 2 mg and Metformin 850 mg BID | -0.95 |
The change between the value of High Sensitivity C-reactive Protein less than or equal to 10 mg/L collected at week 24 or final visit and High Sensitivity C-reactive Protein less than or equal to 10 mg/L collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/L (Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -0.87 |
| Glimepiride 2 mg and Metformin 850 mg BID | 0.00 |
The change between the value of High Sensitivity C-reactive Protein collected at week 24 or final visit and High Sensitivity C-reactive Protein collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/L (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -0.21 |
| Glimepiride 2 mg and Metformin 850 mg BID | -0.04 |
The change between HDL-Cholesterol collected at week 24 or final visit and HDL-Cholesterol collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 3.3 |
| Glimepiride 2 mg and Metformin 850 mg BID | -0.4 |
The change between High-Density Lipoprotein/Low-Density Lipoprotein Ratio collected at week 24 or final visit and High-Density Lipoprotein/Low-Density Lipoprotein Ratio collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 0.1 |
| Glimepiride 2 mg and Metformin 850 mg BID | 0.3 |
The change between Low-Density Lipoprotein Cholesterol collected at week 24 or final visit and Low-Density Lipoprotein Cholesterol collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 9.7 |
| Glimepiride 2 mg and Metformin 850 mg BID | 11.2 |
The change between the value of Low-Density Lipoprotein Subfractions collected at week 24 or final visit and Low-Density Lipoprotein Subfractions collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 6.2 |
| Glimepiride 2 mg and Metformin 850 mg BID | 6.1 |
The change between the value of Baseline in Matrix Metallo Proteinase-9 collected at week 24 or final visit and Baseline in Matrix Metallo Proteinase-9 collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | ng/mL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 31.4 |
| Glimepiride 2 mg and Metformin 850 mg BID | 51.6 |
The change between the value of Nitrotyrosine collected at week 24 or final visit and Nitrotyrosine collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | nmol/L (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -2.7 |
| Glimepiride 2 mg and Metformin 850 mg BID | 32.5 |
The change between the value of Platelet Function by PFA 100 collected at week 24 or final visit and Platelet Function by PFA 100 collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | sec (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -30.3 |
| Glimepiride 2 mg and Metformin 850 mg BID | -1.0 |
The change between the value of Soluble CD40 Ligand collected at week 24 or final visit and Soluble CD40 Ligand collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | pg/mL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -40.7 |
| Glimepiride 2 mg and Metformin 850 mg BID | 102.4 |
The change between the value of Baseline in Soluble Intracellular Adhesion molecule at week 24 or final visit and Baseline in Soluble Intracellular Adhesion molecule collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | ng/mL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -13.0 |
| Glimepiride 2 mg and Metformin 850 mg BID | -3.2 |
The change between the value of Soluble Vascular Cell Adhesion Molecule collected at week 24 or final visit and Soluble Vascular Cell Adhesion Molecule collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | ng/mL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 11.6 |
| Glimepiride 2 mg and Metformin 850 mg BID | 3.3 |
The change between Systolic Blood Pressure measured at week 24 or final visit and Systolic Blood Pressure measured at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -2.5 |
| Glimepiride 2 mg and Metformin 850 mg BID | 0.5 |
The change between the value of Thromboxane B2 collected at week 24 or final visit and Thromboxane B2 collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | pg/mL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -216.4 |
| Glimepiride 2 mg and Metformin 850 mg BID | 527.8 |
The change between the value of Triglycerides collected at week 24 or final visit and Triglycerides collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -40.9 |
| Glimepiride 2 mg and Metformin 850 mg BID | -16.7 |
The change between the value of Von-Willebrand Factor collected at week 24 or final visit and Von-Willebrand Factor collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | percent (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -19.5 |
| Glimepiride 2 mg and Metformin 850 mg BID | 1.4 |
The change between the Intake of study medication greater than 80% at week 24 or final visit and Baseline and the Intake of study medication greater than 80% at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | participants (Number) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 136 |
| Glimepiride 2 mg and Metformin 850 mg BID | 137 |
The increase in High-Density Lipoprotein (HDL) Cholesterol collected at week 24 or final visit and HDL-Cholesterol collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 3.2 |
| Glimepiride 2 mg and Metformin 850 mg BID | -0.3 |
11 reviews available for pioglitazone and Dyslipidemia
| Article | Year |
|---|---|
Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Glucagon-Like Peptid | 2017 |
Pathophysiology of Diabetic Dyslipidemia.
Topics: Animals; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Chylomicrons; Diabetes | 2018 |
Gender-specific risk factors for gout: a systematic review of cohort studies.
Topics: Age Factors; Animals; Body Size; Body Weight; Cohort Studies; Diabetes Complications; Diet; Diuretic | 2019 |
Nonalcoholic fatty liver disease: new treatments.
Topics: Antioxidants; Cardiovascular Diseases; Dyslipidemias; Humans; Hypoglycemic Agents; Insulin Resistanc | 2015 |
Pioglitazone and rosiglitazone: effects of treatment with a thiazolidinedione on lipids and non conventional cardiovascular risk factors.
Topics: Adipose Tissue; Apolipoproteins; Atherosclerosis; Cardiovascular Diseases; Dyslipidemias; Humans; Hy | 2008 |
The differential effects of thiazolidindiones on atherogenic dyslipidemia in type 2 diabetes: what is the clinical significance?
Topics: Biomarkers; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Hypoglycemic Agents; Lipoproteins, HDL | 2008 |
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management.
Topics: Bariatric Surgery; Biomarkers; Biopsy; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type | 2009 |
[Japanese Guidelines for the Management of Stroke 2009 : important revised points necessary for the neurologist].
Topics: Aspirin; Atorvastatin; Cilostazol; Diabetes Complications; Dyslipidemias; Evidence-Based Medicine; H | 2010 |
Pioglitazone: a review of its use in type 2 diabetes mellitus.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Drug T | 2006 |
The metabolic basis of atherogenic dyslipidemia.
Topics: Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; D | 2005 |
[Therapy with glitazones--a risk for cardiovascular disease?].
Topics: Cardiovascular Diseases; Cholesterol, LDL; Contraindications; Diabetes Mellitus, Type 2; Dyslipidemi | 2007 |
16 trials available for pioglitazone and Dyslipidemia
| Article | Year |
|---|---|
Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study).
Topics: Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; | 2020 |
Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Cardiovascular Diseases; Diabetes Mellitus, Type | 2017 |
Pioglitazone attenuates cardiometabolic risk factors in non-diabetic patients with dyslipidemia.
Topics: Adult; Aged; Body Mass Index; Body Weight; Dyslipidemias; Female; Gemfibrozil; Humans; Hypoglycemic | 2017 |
Relationship between resolution of non-alcoholic steatohepatitis and changes in lipoprotein sub-fractions: a post-hoc analysis of the PIVENS trial.
Topics: Adult; Biomarkers; Biopsy; Dyslipidemias; E-Selectin; Female; Humans; Intercellular Adhesion Molecul | 2019 |
Fenofibrate increases serum vaspin by upregulating its expression in adipose tissue.
Topics: 3T3-L1 Cells; Adipocytes; Adult; Animals; Disease Models, Animal; Dyslipidemias; Fenofibrate; Humans | 2014 |
Effects of pioglitazone on macrovascular events in patients with type 2 diabetes mellitus at high risk of stroke: the PROFIT-J study.
Topics: Aged; Aged, 80 and over; Blood Pressure; Diabetes Complications; Diabetes Mellitus, Type 2; Dyslipid | 2014 |
No improvement of high-density lipoprotein (HDL) vasorelaxant effect despite increase in HDL cholesterol concentration in type 2 diabetic patients treated with glitazones.
Topics: Aged; Animals; Aorta; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dyslipidemias; Endothelium, Vascu | 2014 |
Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Dyslipidemias; Female; | 2014 |
Withdrawal of pioglitazone in patients with type 2 diabetes mellitus.
Topics: Adiponectin; Alkaline Phosphatase; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Sch | 2010 |
[Study of MDA-LDL by pioglitazone and pitavastatin in patients with type 2 diabetes].
Topics: Aged; Arteriosclerosis; Biomarkers; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus, Ty | 2011 |
PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia.
Topics: Adiponectin; Aged; Anticholesteremic Agents; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; | 2011 |
Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.
Topics: Adult; Aged; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; | 2005 |
Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy.
Topics: Adolescent; Adult; Aged; Apolipoproteins; Blood Glucose; Blood Pressure; C-Reactive Protein; Cholest | 2006 |
Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Dyslipidemias; Fatty Acids, Nonesterified; Glycated | 2007 |
The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin.
Topics: Adult; Alkanesulfonates; Anticholesteremic Agents; Atorvastatin; Chemotherapy, Adjuvant; Cross-Over | 2007 |
The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
Topics: Aged; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dru | 2008 |
16 other studies available for pioglitazone and Dyslipidemia
| Article | Year |
|---|---|
Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia.
Topics: Animals; Blood Glucose; Butyric Acid; Cell Line; Cholesterol; Cricetinae; Diabetes Mellitus, Type 2; | 2009 |
Modulation of Insulin Resistance, Dyslipidemia and Serum Metabolome in iNOS Knockout Mice following Treatment with Nitrite, Metformin, Pioglitazone, and a Combination of Ampicillin and Neomycin.
Topics: Ampicillin; Animals; Drug Therapy, Combination; Dyslipidemias; Glucose; Homeostasis; Hypoglycemic Ag | 2021 |
Diabetes as First Manifestation of Autoimmune Pancreatitis.
Topics: Adrenal Cortex Hormones; Aged; Autoimmune Diseases; Diabetes Complications; Diabetes Mellitus; Dysli | 2017 |
Beta-caryophyllene protects against diet-induced dyslipidemia and vascular inflammation in rats: Involvement of CB2 and PPAR-γ receptors.
Topics: Animals; Diet; Dyslipidemias; Inflammation; Male; Pioglitazone; Polycyclic Sesquiterpenes; PPAR alph | 2019 |
Comparison of the effects of sulforaphane and pioglitazone on insulin resistance and associated dyslipidemia, hepatosteatosis, and endothelial dysfunction in fructose-fed rats.
Topics: Animals; Aorta, Thoracic; Blood Glucose; Body Weight; C-Reactive Protein; Dyslipidemias; Fatty Liver | 2019 |
Non-glycemic effects of pioglitazone and incretin-based therapies.
Topics: Body Weight; Cardiovascular Diseases; Dyslipidemias; Humans; Hypoglycemic Agents; Incretins; Pioglit | 2013 |
Resistant nonalcoholic fatty liver disease amelioration with rosuvastatin and pioglitazone combination therapy in a patient with metabolic syndrome.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Diabetes Mellitus, Type 2; Drug Resistance; Drug | 2014 |
Hyperinsulinaemic androgen excess in adolescent girls.
Topics: Adolescent; Androgens; Drug Therapy, Combination; Dyslipidemias; Female; Flutamide; Hirsutism; Human | 2014 |
A Novel Partial Agonist of Peroxisome Proliferator-Activated Receptor γ with Excellent Effect on Insulin Resistance and Type 2 Diabetes.
Topics: 3-Mercaptopropionic Acid; Animals; Blood Glucose; Cell Line; Cell Survival; Diabetes Mellitus, Exper | 2015 |
Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US.
Topics: Aged; Cohort Studies; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Dise | 2008 |
Rhesus macaques develop metabolic syndrome with reversible vascular dysfunction responsive to pioglitazone.
Topics: Animals; Blood Vessels; Disease Models, Animal; Disease Progression; Dyslipidemias; Hyperinsulinism; | 2011 |
PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia.
Topics: Animals; Apolipoprotein E2; Apolipoproteins E; Atherosclerosis; Blood Glucose; Disease Models, Anima | 2005 |
Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice.
Topics: Animals; Aorta, Thoracic; Apolipoproteins E; Atherosclerosis; ATP Binding Cassette Transporter 1; AT | 2006 |
The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats.
Topics: Adipose Tissue; Animals; Blood Glucose; Carbazoles; Disease Models, Animal; Dyslipidemias; Gene Expr | 2006 |
Case report of Klinefelter's syndrome with severe diabetes, dyslipidemia, and stroke: The effect of pioglitazone and other anti-inflammatory agents on interleukin-6 and -8, tumor necrosis factor-alpha, and C-reactive protein.
Topics: Adult; Anti-Inflammatory Agents; C-Reactive Protein; Diabetes Mellitus; Dyslipidemias; Humans; Inter | 2006 |
[Determining the current position regarding the value of pioglitazone for the therapy of diabetes].
Topics: Animals; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Fractures, Bone; Glycate | 2007 |